Get started

Johnson_and_johnson

Johnson & Johnson | Fundamental Analysis | LONG SETUP ⚡️For much of the previous decade, the stock of diversified healthcare behemoth Johnson & Johnson has consistently delivered market returns (if you count dividends as part of total return on equity). Investors flocked to this company because of its solid balance sheet, its status as a dividend aristocrat, and its unique ability to consistently bring new blockbuster pharmaceutical products to market in a timely manner. Since the beginning of this decade, however, J&J stock has largely underperformed the broader markets. The stock has lost its luster recently because of the baby powder litigation, the lack of enthusiasm among investors for the $30 billion acquisition of Actelion, the maker of pulmonary arterial hypertension drugs, its high valuation, and the relatively low sales of its COVID-19 vaccine. Will J&J stock be able to return to its previous market successes or should investors move to a more favorable environment? Here's a look at both sides of the question. 1. J&J may be one of the top stocks in healthcare today, but this $444 billion titan is about to undergo some major changes that could lead to a decline in its performance. According to a Nov. 12 announcement, the company plans to split into two businesses over the next 24 months. One of the new businesses will focus on consumer health products and the other on the development and commercialization of pharmaceuticals and medical devices. The transition will be one of the largest in the company's 135-year history, and it will entail reshuffles in all areas, including senior management. This means that serious risks loom on the horizon that shareholders have not yet had to deal with. Splitting the business in two may turn out for the best, but it's important to remember that things haven't been going in the right direction for some time. Over the past five years, quarterly revenue has grown by only 28.9 percent, while quarterly profit margins have fallen by 25.4 percent. Similarly, quarterly net income is down 3.85% and quarterly free cash flow (FCF) is down more than 19% over the same period. There is no guarantee that the separation will solve these problems. In addition to the uncertainties associated with the separation, the company also faces new hurdles regarding revenue from the coronavirus vaccine, which is expected to bring in $2.5 billion in 2021. On Dec. 16, the Centers for Disease Control and Prevention issued a recommendation that the company's vaccine should not be used if vaccines from competitors such as Pfizer are available. The recommendation comes amid ongoing concerns about the J&J vaccine's poor efficacy and its ability to cause rare and life-threatening complications in some people. Therefore, this is a particularly risky time to invest in J&J stock. Time will tell if the company can gracefully survive its breakup. 2. Wall Street has not been particularly receptive to J&J's proposed separation and for good reason. After all, the company's health care division contains several iconic brands, such as Benadryl and Tylenol, which are proven cash cows. Wall Street's fears about this separation, however, may have been exaggerated. As evidence, Pfizer recently went through a slimming process, separating its legacy products business without any adverse consequences. And J&J, for its part, seems more than capable of pulling off the same maneuver without any major hitches. This is evidenced by a wide range of fast-growing pharmaceutical products, such as the multiple myeloma drug Darzalex, the immune-mediated inflammatory disease drug Stelara, and the plaque psoriasis drug Tremfya. It was these three key products that drove the company's pharmaceutical segment in the third quarter of 2021, up 13.8% from a year ago, excluding acquisitions and sales. Moreover, J&J is one of the best in the business at launching new pharmaceutical products for areas with large unmet medical needs. In fact, this separation should allow the company's pharmaceutical division to shine from a top-line perspective. And that's a big plus for growth-oriented investors. Income investors may be concerned about the potential impact on the company's much-desired dividend. Fortunately, J&J management has already said that future dividend payments should remain about the same as the current quarterly distribution after the split. Overall, J&J stock seems poised to turn into a top play for growth and earnings after the upcoming split.
NYSE:JNJLong
by FOREXN1
JNJ Formed a nice Double Bottom patternHi everyone, $JNJ formed a nice Double Bottom pattern on Daily timeframe . The price hit twice the strong support formed at around 155 price level. It recently broke the resistance level at 167 and now it is ready to test it again as a support level. If tested successfully it offers a really nice buy setup. If you like the idea, do not forget to support with a like and follow. * 𝗧𝗵𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗵𝗮𝗿𝗲𝗱 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗽𝗼𝘀𝘁 𝗶𝘀 𝗻𝗼𝘁 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗮𝗱𝘃𝗶𝗰𝗲 𝗮𝗻𝗱 𝗶𝘀 𝗳𝗼𝗿 𝗲𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗽𝘂𝗿𝗽𝗼𝘀𝗲 𝗼𝗻𝗹𝘆! 𝗔𝗹𝘄𝗮𝘆𝘀 𝗰𝗼𝗻𝗱𝘂𝗰𝘁 𝘆𝗼𝘂𝗿 𝗼𝘄𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗮𝗻𝗱 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵.
NYSE:JNJLong
by preduta
Johnson & Johnson | Fundamental Analysis | Must Read...Johnson & Johnson is a leader in several areas of pharmaceutical research, including oncology and immunologic diseases. The company's portfolio of drugs in these two areas brings in billions of dollars in revenue each quarter. The company is currently seeking to strengthen its market share in COVID-19 vaccines. This year, Johnson & Johnson anticipates generating $2.5 billion from sales of its COVID-19 vaccine, well below the $33.5 billion and $20 billion, respectively, expected by Pfizer and Moderna. Fortuitously, some up-to-date developments favor Johnson & Johnson's ambitions in this profitable market. Most COVID vaccines currently available in the U.S. are given to patients in two doses about a month apart. J&J's vaccine is injected in only one dose. Based on real-world data and Phase 3 clinical trials, the company is sure that a single dose of its vaccine is 75% effective against severe cases of COVID for at least 28 days after vaccination. This efficacy compares disadvantageously with the effectiveness of vaccines marketed by Pfizer and Moderna, as well as a vaccine developed by Novavax, which has not yet received emergency use authorization (EUA) in the United States. All three vaccines have proven at least 90% effective in preventing COVID in clinical trials. Nevertheless, Johnson & Johnson recently revealed data showing that a booster dose (or second dose) of the vaccine, given two months after the first dose, improves its effectiveness to 94% against the onset of severe COVID. On Oct. 5, the company applied for EUA approval from the Food and Drug Administration (FDA) to administer a second dose of the vaccine. Then, on Oct. 15, a panel convened by the FDA voted unanimously for the agency to issue the company an EUA approval. The last wek, the FDA granted the company this long-awaited approval. In addition to getting the green light a little later than some of its competitors, Johnson & Johnson's COVID vaccine faced several obstacles. In mid-April, health authorities decided to suspend the distribution of the vaccine after it was suspected of causing blood clots in some patients (the original EUA approval was granted in late February). Regulators canceled that suspension about a week and a half later, arguing that the known benefits outweighed the known risks and requiring a new warning on the vaccine label going forward. Indeed, six patients out of more than 6.8 million vaccinated were known to have been affected by this adverse event. This episode is now left behind, but since the pandemic is not yet over, mainly because of the more dangerous delta variant of the virus, the need for vaccines remains. Since the second dose of the J&J vaccine seems to increase its effectiveness, this can only have a positive effect on its sales. This is especially true given that the FDA has not placed any health-related (or similar) restrictions on who can get a second dose of the vaccine from Johnson & Johnson. But here's the catch: the company has pledged not to profit from the product for the duration of the pandemic. In other words, boosted sales of vaccines will have no meaningful impact on the bottom line in the short term. In the future, the company may profit from its vaccine when the pandemic fades and if COVID becomes a seasonal disease like the flu, as some predict. But even then, given how competitive this market is, the J&J vaccine will have only a very moderate influence on a company that typically makes more than $10 billion in profits a year. In other words, investing in Johnson & Johnson because of its COVID vaccine is not a good idea. Luckily, there are plenty of other reasons for that. Consider the company's diversified operations. Its pharmaceutical business, the largest by revenue, includes quite a few blockbuster products whose sales continue to grow. Here are a few of them: in the third quarter (ended Sept. 30), revenue from the immunosuppressant Stelara was $2.4 billion, up 22.2% from the previous quarter. Oncology drug Darzalex increased its sales 43.7% year over year to $1.6 billion. This is just the tip of the iceberg for the company, with several dozen late-stage programs in development. Expanding its product line and approving new drugs is commonplace at Johnson & Johnson. Its consumer health products segment sells over-the-counter products with broad appeal, including Listerine, Neutrogena, Aveeno, and Tylenol. The company's medical device business adds to its revenue base. Here's another reason to invest in this company: the company has increased its dividend every year for more than 50 consecutive years, making it the Dividend King. The company currently has a yield of 2.53%, higher than the S&P 500 Index's 1.38%, and maintains a conservative cash payout ratio of 47%. That makes it engaging to income-seeking investors. In other words, Johnson & Johnson may not be the best stock to buy the COVID vaccine, but it remains a solid pharmaceutical company to invest in.
NYSE:JNJShort
by FOREXN1
3
ICP/BUSD Price Action on ICP Cryptocurrency AND "If you had"Hello, in my series "If you had listened to me" Or "If you had followed me" you would see that from July 19th 2021 the price action for Bitcoin was just unreal. You literally could have doubled your money. So now we look at the cryptocurrency called ICP and the amazing price action. Internet Computer (ICP) is a utility token that allows users to participate in and govern the Internet Computer blockchain network. The network aims to help developers create websites, enterprise IT systems, internet services, and DeFi applications by "installing their code directly on the public Internet." ICP can also be staked or "converted into cycles" that can be used to power computation for dApps and traditional applications. I wish I could write more about ICP, however let's put it this way.. It was a token that I have known about since the early days. It's a token I had respect for. I do not have respect for a lot of things which I am working on. So for me to have respect for something means a lot. So get in on the price action and be well.
ILong
by Henrywaters
Johnson & Johnson|Fundamental Analysis|Price action| MUST READ!In a nutshell, Johnson & Johnson's third-quarter results were generally good. The company reported a 10.7% year-over-year increase in revenue to $23.3 billion. Adjusted earnings per share rose 18.2% to $2.60, well above the consensus estimate of $2.35. Given the large earnings outperformance, you'd probably think the health care company's stock should have rallied Tuesday after the quarterly report was released. And you'd be right. J&J stock opened up about 1% and gained even more momentum during the day. Perhaps the rise would have been greater had it not been for the company's third-quarter earnings, which came in below analysts' average forecast of $23.7 billion. But there was more to this story for the health care giant than just the underlying numbers. Here are three things you might have missed about Johnson & Johnson's third-quarter results. First and foremost, three products accounted for 63% of the growth. Many investors love Johnson & Johnson largely because of its diversification. The company has three multi-billion dollar business segments targeting different areas of healthcare. Hundreds of products are sold in these segments. In 2020, J&J claimed 28 products or platforms with annual sales of more than $1 billion. Although Johnson & Johnson's business is broadly diversified, the drivers of its growth in the third quarter were not. Just three products accounted for about 63% of the company's total revenue growth. These products accounted for nearly 90% of J&J's pharmaceutical sales growth. Not surprisingly, the COVID-19 vaccine tops the list. It brought in $502 million in the third quarter, up from no revenue the previous year. The multiple myeloma drug Darzalex took a respectable second place. Sales of the drug totaled $1.58 billion in the third quarter, up 43.7% from nearly $1.1 billion in the same quarter in 2020. J&J's Stelara drug was the third-largest growth driver in the third quarter. Sales of the plaque psoriasis and psoriatic arthritis drug totaled $2.38 billion in the quarter. That's a 22.2% increase over sales of $1.95 billion in the previous quarter. Second, it's important to keep in mind that the COVID-19 pandemic continues to have a major impact beyond just the vaccine. Johnson & Johnson's COVID-19 vaccine certainly contributed significantly to the good third-quarter results. And it could make an even bigger furor in the future. J&J is likely to benefit significantly from booster sales (if, as expected, it gets approved for boosters). However, COVID-19 also continues to have a significant impact on J&J's fortunes beyond the vaccine. Johnson & Johnson's consumer health business, for example, has been helped by increased sales of the drug Tylenol. The company noted that some of the increase in sales of the over-the-counter drug was due to its use to relieve vaccine-induced symptoms. J&J also reported that sales of ORSL HCP electrolyte drinks increased due to relief of COVID-19 symptoms. It wasn't all good news, however. Sales bans in parts of the Asia-Pacific region had a negative impact on sales of baby care products. The company said growth in sales of its Imbruvica cancer drug was partially held back by COVID-19-related dynamics. In addition, sales of J&J's orthopedic medical products in the spine, sports, and other category fell mainly because of the impact of COVID-19 on the market. Finally, the company is now on the cusp of an international tipping point. Although based in the U.S., Johnson & Johnson has been a major competitor in global markets for most of its history. And now the health care giant is nearing a crucial international stage. In the third quarter, J&J's U.S. sales rose 7.9 percent year over year to just under $12 billion. Its international sales jumped 13.8% to $11.4 billion. International markets now account for 48.7% of total revenue. At the current rate of growth, by next year more than half of Johnson & Johnson's revenue will come from outside the United States. Investors should see this as a decidedly positive trend. Greater geographic diversification of revenues could make Johnson & Johnson even more stable than it is now.
NYSE:JNJShort
by FOREXN1
6
JNJ Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:JNJShort
by hadimozayan
JNJ Ready to Continue Rising HigherThe share price of Johnson and Johnson looks ready to rebound from the major resistance-turned-support area, underpinned by the 23.6 per cent Fibonacci retracement level at 175.61, and resume climbing. The underlying uptrend appears to be taking the form of a 1-5 impulse wave pattern, as postulated by the Elliott Wave Theory. Thus, the recent correction can be perceived as the second retracement leg (3-4). If the price action strengthens above the 23.6 per cent Fibonacci, this would allow for the subsequent emergence of the final impulse leg (4-5). If, however, the correction breaks down below the lower limit of the support, underpinned by the 100-day MA (in blue), this would likely mean that it could then be extended lower towards the 38.2 per cent Fibonacci.
NYSE:JNJLong
by Trendsharks
Johnson & Johnson Stock Daily AnalysisHello everyone, as we all know the market action discounts everything :) _________________________________Make sure to Like and Follow if you like the idea_________________________________ The Johnson & Johnson stock is having a great Bullish movement right now, In the last week, the stock price has risen from 173.05 and reached 179.47 today. That's more than 3.7% in 1 week. Both the short-term and long-term trends are positive. This is a very positive sign. We are looking at 2 different Scenarios for the next period of time : Scenario 1 : The price has gone up and reached the resistance zone at 178.51 to 179.17 and its currently above it but it hasn't closed above it yet, That means the market is still moving in a Bullish way but until we have our confirmation we cant say the price is gonna keep going, but all the signs are Bullish After today's candle closes we will have our confirmation and the price will most likely continue his journey up reaching the 180.45 level. Scenario 2 : The price has gone up and reached the resistance zone at 178.51 to 179.17, Here the Bears has a Chance to show some control over the market action, The bulls are testing the Bear right now, And if the Bulls were to fail then the bears will take some control and we will see the price dropping from the resistance zone and its gonna be headed near the support line at 176.57, where a Battle will happen between the Bears and the Bulls and the outcome will determine the movement of the stock for the next period of time. Technical indicators showing this : 1) The Market price is currently trending above the 5 10 20 50 100 and 200 MA and EMA (Bullish sign) 2) The MACD is above the 0 Line showing that the market is in a Bullish state, With a positive crossover between the MACD line and Signal line. 3) The ADX is at 31.68 showing that the market is currently trending, With a positive crossover between DI+ (36.78) and DI- (10.24) Support & Resistance points : support Resistance 1) 176.57 1) 178.51 2) 175.29 2) 179.17 3) 174.63 3) 180.45 Fundamental point of view : JNJ has a Return On Assets of 10.07%. This is amongst the best returns in the industry. The industry average is -32.26%. JNJ outperforms 94% of its industry peers. The Earnings Per Share has grown by a nice 14.55% over the past year. JNJ has an Altman-Z score of 4.59. This indicates that JNJ is financially healthy and has little risk of bankruptcy at the moment. Biden administration officials reportedly plan to recommend booster doses of Pfizer and Moderna’s Covid-19 vaccines to most Americans eight months after they received their second dose. This could Affect the Johnson & Johnson stock as other company's Vaccine such as Pfizer and Moderna is being used far more often and being recorded for giving better result than the JNJ Vaccine . This is my personal opinion done with technical analysis of the market price and research online from fundamental news for The Fundamental point of view, not financial advice. If you have any questions please ask and have a great day !! Thank you for reading.
NYSE:JNJLong
by GabiDahduh
2
JOHNSON & JOHNSON: DETAILED FUNDAMENTAL+FIBO ANALISY|LONG🔔Johnson & Johnson has been a profitable business to invest in for years. But its legal problems have grown steadily--the company has faced tens of thousands of lawsuits over talc alone. And while so far the health care giant has managed to cope with its legal costs and remain profitable, that may not be the case in the future. In addition, all these negative publications are not good for the Johnson & Johnson brand. The constant barrage of recalls and lawsuits could cause real, long-term damage. Can we still invest in this business, or have Johnson & Johnson's legal problems made this company a stock to be avoided at all costs? Johnson & Johnson has been involved in numerous lawsuits in recent years. Most recently, earlier this month, the company announced a voluntary recall of certain Neutrogena and Aveeno sunscreens. Although benzene, a known carcinogen, is not in their composition, it was found in product testing. Johnson & Johnson is recalling the products "for reasons of caution." In addition, the U.S. Food and Drug Administration (FDA) issued a second warning regarding Johnson & Johnson's coronavirus vaccine. It states that the vaccine may increase a person's risk of developing a neurological disorder called Guillain-Barré syndrome. The agency had also previously issued a warning that the vaccine increases the risk of blood clots. (The FDA also issued warnings for Pfizer and Moderna's COVID-19 vaccines, saying they increase the risk of heart inflammation.) These cases have not caused problems with Johnson & Johnson's financial performance - yet. In 2020 and 2019, Johnson & Johnson's legal expenses totaled more than $5 billion. However, in each of those years, the company's net income was about $15 billion. And as a percentage of revenue, the company made an 18 percent profit - only slightly less than the 19 percent net income it achieved in 2018. From a purely financial standpoint, the company has yet to feel much of an impact on its bottom line. When Johnson & Johnson released its latest quarterly results on July 21, its earnings for the period ending April 4 looked higher than ever, at more than $6 billion. But as problems mount, legal costs could rise sharply in the coming years. And rumor has it that the company is looking ahead to potentially limit some of that liability. According to a Reuters report, Johnson & Johnson is considering writing off liabilities related to baby powder talcum powder to a new business and then putting that business under bankruptcy protection. The move would help limit the company's legal liabilities related to the issue. Johnson & Johnson is an incredibly profitable company, and its stock is the king of dividends you can count on for the foreseeable future - provided, of course, that legal bills don't begin to undermine the company's ability to meet those obligations. At present, that doesn't seem to be a problem. However, investors should be careful not to rely solely on past performance or on the company's ability to weather the storm. The more problems become known, the more likely the company is to suffer financial losses in one form or another. We have no way of knowing whether a particular straw will be found that will break the camel's back, and it certainly seems unlikely now that Johnson & Johnson will not survive these problems, given its enormous size. But mere survival will not make this company a great investment. There are also intangibles to consider, such as the impact of bad headlines on the company's future and whether it might cause consumers to switch to competing brands. It, combined with potentially rising litigation costs, creates some long-term risk that investors shouldn't just ignore. And if a company is trying to dodge responsibility to consumers who have developed serious health problems related to talcum powder, it could alienate potential investors from an ethical standpoint. While Johnson & Johnson is doing well right now, there are better options for investors that don't have nearly as much long-term risk.
NYSE:JNJLong
by FOREXN1
7
Are Covid Stocks Coming Back?If there is any hope for the S&P right now it may very well come from the healthcare sector with mega blue chip Johnson & Johnson. JNJ has managed to put in consecutive higher highs and higher lows on the weekly, and now also is confirming support on the .618 fibonacci level at $165.40. However, there appears to still be much selling pressure at just above $168, so don't be surprised if we continue to see consolidation for another a week or two before getting the confirmed breakout above our red resistance line at the aforementioned $168 price level. If resistance at this level is broken, we will be seeing a possible retest of blue sky all time highs for the healthcare giant JNJ. In the meantime, I am liking the idea of small longs along the .618 ($165.40) area as long as the upward sloping green trend is not violated.
NYSE:JNJLong
by TradeVibez
JNJ Will the $200 stop a protracted and non-corrective rally?Johnson & Johnson is a major manufacturer of cosmetic and sanitary products, as well as medical equipment and medicines. The company was founded in 1886. In general, the history of the company is mega-successful. The corporation expanded through the purchases of competitors and gained more and more market share in its areas. The company's progress is confirmed by the capitalization, which exceeds $430bn , as well as the graph of the JNJ share price, which is growing parabolic. For 10 years, from 2002 to 2012, smart and patient investors recruited long positions in JNJ shares. During this period, the price traded in a broad consolidation of $46-71, growing volumes talked all - patience and everything will be) From 2012 to the present, the value of JNJ shares has grown practically without correction. Even during the Covid market plunge in February-March 2020, JNJ shares fell by only -29%. For example, then the S&P500 fell by -35%, the DJI index -38%, and the shares of the hype TSLA by as much as -60%. The investors in this company knew and believed and they did not lose, because during the COVID-19 pandemic, a subsidiary of Johnson & Johnson, Janssen Pharmaceutica, developed a vaccine against this virus, which is certified for use in the USA and the EU, and the value of JNJ shares has renewed its absolute maximum. Since the beginning of the year, JNJ's share price has been pushed towards the important $171 level . After the price fixes above this level, another upward impulse will take place. We assume that it may be final before the start of a prolonged downward correction. In the region of $195-200, it is better to fix the longs and look around, because the correction can be deep enough, and enough people who want to buy JNJ shares again may be in the $ 84-96 zone.
NYSE:JNJ
by P_S_trade
24
Johnson and Johnson Struggling Below a Historic Resistance The share price appears unable to break out above the historic resistance level at 170.00, which represents a very strong bearish signal. Moreover, the price action has recently established a broad 1-5 impulse wave pattern, as postulated by the Elliott Wave Theory, as well as having developed an Ascending Wedge. Both of these developments confirm the bearish expectations. Finally, yesterday's trading session resulted in the creation of a Shooting Star candle, which could be a precursor to an imminent reversal. Overall, there seems to be a very strong confluence of bearish indications at present. The 23.6 and 38.2 per cent Fibonacci retracement levels represent the most likely targets for such a dropdown.
NYSE:JNJShort
by Trendsharks
JOHNSON & JOHNSON (JNJ)In my work, I always try to combine fundamental analysis and technical analysis. They are both important, especially on a topic as important as the covid vaccine. Johnson & Johnson is about to be marketed, after the approval of the EMA on 11 March. Exactly after the announcement, I bought the stock. The JnJ vaccine has a much lower distribution cost than Pfizer since it can be stored at refrigerator temperatures, like AstraZeneca. The difference is in the prestige and history that the company has. Moreover, the share according to the average of analysts, still has ample room for growth, with an average target of $ 185 and a second "high" at $ 200. Technically speaking, the price bounced off the bullish support trendline on Thursday, March 4th, and then broke the resistance trendline on the 12th, exactly the day after the announcement of the EMA's approval. The trend is clearly bullish, but, even keeping in mind the analysts' opinion, I believe the first target in area 170 is more likely. If everything goes well with the vaccine, the analyst targets could be greatly raised. It is a different trade, to be constantly monitored with a trailing stop, in case there will be any hitches or cases of a block, as happened for AstraZeneca. Such an open market scenario would cause a crash, so you have to be ready to get out quickly. Lazy Bull 1st target: 170 2nd target: 180 3rd target: 200 DISCLAIMER: I am not a financial advisor nor a CPA. These posts, videos, and any other contents are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
NYSE:JNJLong
by LazyBull5
2
Johnson & Johnson should stick to baby wipes.....Vaccine Recall!With the news that the CDC is pausing J&J vaccine distribution due to blood clot issues. I'm assuming we should see it tank at the open? You're guess is as good as mine. In my opinion if we see price drop it should be a good time to buy, because everyone else is selling. The level I'm interested in is $147-$150. It is an untested point of control where institutions may have some buy orders sitting. Watch for an ABCD on the line chart (close to close) for entry. We may not break the 2021 high, but if the March equal highs remain untouched, I would look to enter because there is still possibly liquidity there. $150 should give a nice reaction if we hit it while those highs are untouched. Let's Elevate, Gio
NYSE:JNJ
by elevatedinvestor